title: Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.
abstract: Brentuximab vedotin has emerged as a useful treatment option for relapsed or refractory Hodgkin's lymphoma; however, uncommon cases of anaphylactic reactions may require its permanent discontinuation. We report a 29-yr-old woman with refractory Hodgkin's lymphoma, who developed an anaphylactic reaction during the second dose of brentuximab vedotin. A 12-step desensitization protocol was followed; after premedicating with antihistaminic agents, methylprednisolone and montelukast, a total dose of 156 mg of brentuximab vedotin (1.8 mg/kg) was given as three infusions with increasing rate and concentration. Such desensitization protocol can allow safe administration of brentuximab vedotin and may have a broader applicability in managing hypersensitivity reactions with other monoclonal antibodies.
authors.affiliation: Department of Obstetrics and Gynecology, King George's Medical College, Lucknow, India.
authors.forename: Anubha
authors.initials: A
authors.lastname: Arora
authors.affiliation: Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
authors.forename: Vijaya Raj
authors.initials: VR
authors.lastname: Bhatt
authors.affiliation: Blood and Marrow Transplant Unit, Department of Pharmacy, Nebraska Medicine, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
authors.forename: Susanne
authors.initials: S
authors.lastname: Liewer
authors.affiliation: Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
authors.forename: James O
authors.initials: JO
authors.lastname: Armitage
authors.affiliation: Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
authors.forename: R Gregory
authors.initials: RG
authors.lastname: Bociek
mesh_terms: D000328:Adult; D000707:Anaphylaxis / Q000188:drug therapy* / Q000209:etiology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000079963:Brentuximab Vedotin; D003888:Desensitization, Immunologic; D004342:Drug Hypersensitivity / Q000188:drug therapy*; D005260:Female; D006689:Hodgkin Disease / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D000079963:Brentuximab Vedotin
keywords: Hodgkin's lymphoma; anaphylaxis; brentuximab vedotin; desensitization